When the Market Tightens, Your Execution Gaps Stop Hiding

I've spent years working inside and alongside MedTech commercial organizations. And one pattern shows up consistently, regardless of company size, product category, or market position:

When the market is growing, bad execution is invisible. When the market tightens, it's the first thing everyone sees.

That's the uncomfortable truth behind what I call Revenue Friction: the hidden drag inside your commercial model that growth can hide. Slow follow-up. Fragmented handoffs. Weak stakeholder visibility. Misaligned teams. Post-sale gaps that quietly erode the value you and your team worked hard to create.

None of it shows up on a strategy slide. All of it shows up in the numbers.

The Market Has Changed. Has Your Execution?

McKinsey's latest MedTech outlook projects overall revenue growth stabilizing at roughly 100 to 150 basis points above pre-pandemic rates. That sounds manageable until you realize how much execution slack that eliminates.

Source: McKinsey, What to expect from medtech in 2024 (February 2024).

For years, many MedTech commercial organizations operated with the benefit of the doubt. A strong product in a growing market forgives a lot. Slow response times, inconsistent handoffs, uneven account planning: these things cost money, but they don't always cost deals. Not when the tide is rising.

A stable or declining market changes that calculus entirely. Suddenly, every execution gap is a competitive disadvantage. The friction that was always there is now visible to your leadership, your customers, and your competitors.

The question isn't whether friction exists in your commercial model. It does. The question is whether you can see it clearly enough to act on it before it compounds into a miss.

What Revenue Friction Actually Looks Like

Revenue friction isn't one thing. It's a pattern of small, often invisible gaps across the commercial process that collectively slow momentum, erode trust, and reduce the value of every deal you close.

In my work with MedTech organizations, it tends to show up in five consistent places:

• Lead response time: Elevated intent has a short shelf life. InsideSales research has shown that conversion rates can drop dramatically after just minutes of delay. In MedTech, where a conference inquiry or capital request represents real intent, slow follow-up is real revenue loss.
• Handoff quality: Marketing to field. Field to clinical. Clinical to contracting. Each transition is a moment where context, trust, and commercial momentum can be lost. Salesforce's research on sales and marketing alignment confirms what I see in practice: when teams aren't working from shared data and shared accountability, execution gaps widen.
• Stakeholder coverage: The physician champion is not the buying group. Procurement, finance, IT, value analysis, legal: each evaluates something different. Korn Ferry's research on large account selling makes this plain: teams need a clear view of every stakeholder's needs and influence before they can build real buy-in. Gaps in that coverage show up late in the process and feel like surprises.
• Post-sale execution: The contract is signed. That's when many commercial teams disengage. But in MedTech, the sale is the beginning of utilization, adoption, trust, and expansion. When onboarding is weak and early support doesn't match the promise made during the sale, the account starts drifting before the ink is dry.
• Strategy-to-execution drift: The plan looks right. The product is strong. The people are capable. But the quarter closes and the numbers don't match the narrative. This is almost never a strategy problem. It's a visibility problem. Leaders can't see where execution is drifting until it's already a miss.

Sources: InsideSales Lead Response Management Study; Salesforce, Smarketing: A Smart Strategy to Align Sales and Marketing (2026); Korn Ferry, 5 Key Steps to Get Buy-In from Diverse Stakeholders in Large Accounts (2024).

Why This Is a Diagnostic Problem, Not a Motivation Problem

When revenue stalls in a steady market, the instinct is often to push harder: more calls, more campaigns, more pipeline reviews. But activity without clarity just creates motion. And in my experience, motion without insight is expensive.

The organizations that navigate steady markets best are the ones that slow down long enough to diagnose before they prescribe.

That means asking different questions. Not 'why aren't we closing more deals?' but 'where exactly is momentum getting lost?' Not 'why is the pipeline weak?' but 'what's happening between the first conversation and the signed contract?'

It also means being honest about what you can and can't see. Most MedTech commercial leaders have access to CRM data, pipeline reports, and sales metrics. Very few have visibility into the in-between: the handoff quality, the response time reality, the stakeholder map gaps, the post-sale drift.

That's the diagnostic blind spot. And it's where revenue friction lives.

Where AI Fits, and Where It Doesn't

I want to be direct about this, because I see the mistake made frequently: AI is not a strategy. It's a capability. And like any capability, it performs in proportion to the clarity of the problem it's solving.

The most valuable AI applications in MedTech commercial work are the ones that address specific friction points: lead prioritization, stakeholder mapping, handoff documentation, post-sale utilization monitoring. These are high-frequency, high-context tasks that consume real time and generate real risk when done inconsistently.

Gartner's research on B2B buying behavior makes clear that complex buying groups disengage when the seller experience feels fragmented or inconsistent. AI can help address that, but only when the workflow is defined and the ownership is clear.

Applied to a fragmented process, AI just automates the confusion.

Source: Gartner, The New B2B Buying Journey and Its Implications for Sales (2023).

The Right Starting Point

Before any technology conversation, before any campaign adjustment, before any pipeline review, start here:

• Map your actual commercial process, not the ideal version. Where do handoffs happen? Who owns each stage? What information transfers, and what gets lost?
• Identify where momentum reliably slows. Is it at lead response? At stakeholder coverage? At contracting? At post-close adoption? The pattern will tell you where friction is highest.
• Separate execution gaps from strategy gaps. Most of the time, the strategy is sound. The gap is in the distance between strategy and results, and that distance is what we're solving for.

Revenue friction in a steady market isn't a crisis. It's a diagnostic opportunity. The organizations that treat it that way, that use market pressure as a forcing function for operational clarity, emerge with commercial models that are more efficient, more visible, and more resilient.

That's what this series is about. And that's the work RevRx AI was built to do.

Question for you: Where does your commercial process lose the most momentum right now, before the close or after it?